Carlos Arteaga
Faculty Member
Last active: 5/27/2014

Profile

Carlos L. Arteaga obtained his M.D. degree with honors in 1980 at the Facultad the Ciencias M¿¿dicas of the University of Guayaquil in Guayaquil, Ecuador. He trained in Internal Medicine and Medical Oncology at Emory University (Atlanta, GA) and the University of Texas Health Sciences Center in San Antonio, TX, respectively. He joined Vanderbilt in 1989 where he now holds the Donna S. Hall Chair in Breast Cancer Research and serves as Professor of Medicine and Cancer Biology. Dr. Arteaga is also Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center (VICC) where he leads the Breast Cancer Program and the recently founded Center for Cancer Targeted Therapies. He has over 250 publications in the areas of signaling by growth factor receptors and oncogenes in breast tumor cells, development of targeted therapies and biomarkers of drug action or resistance in breast cancer, and investigator-initiated clinical trials. His work includes the first demonstration that blockade of IGF-I receptor results in an antitumor effect in breast cancer; the first observation that tumor-host TGF¿¿¿-mediated interactions are critical for breast tumor establishment and metastatic progression, thus providing a basis for the targeting of TGF¿¿¿ in cancers with a therapeutic intent; one of the first observations that loss of tumor suppressor PTEN confers resistance to ERBB receptor-targeted therapies; the role of p27 haploinsufficiency in breast cancer progression; and the role of PI3K signaling on resistance to antiestrogens in breast cancer.

Since 2002, he has directed the NCI-funded Vanderbilt Breast Cancer Specialized Program of Research Excellence (SPORE) where he co-leads several investigator-initiated clinical trials. He is funded by the National Cancer Institute, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C) and the Susan G. Komen for the Cure and Breast Cancer Research Foundations. He is a member of the American Society of Clinical Investigation (1998) and the Association of American Physicians (2005). He served as member of the Experimental Therapeutics-2 NIH Study Section (1998-2003), the NCI Board of Scientific Counselors (1999-2004), NCI Parent Subcommittee A for review of Cancer Centers (2004-2008), the Breast Core Committee of the Eastern Cooperative Oncology Group (ECOG), and the Board of Directors of the American Association for Cancer Research (2004-2007). He co-chaired the former Developmental Therapeutics Committee of ECOG and chaired the AACR Special Conferences Committee (2002-2008). Arteaga is the recipient of the 2003 AACR Richard & Hinda Rosenthal Award, the 2007-2017 ACS Clinical Research Professor Award, the 2009 Gianni Bonadonna Award from the American Society of Clinical Oncology (ASCO) and the 2011 Brinker Award for Scientific Distinction from the Susan G. Komen for the Cure Foundation. As of this year, he serves in the Scientific Advisory Board of the Susan G. Komen for tehe Cure Breast Cancer Foundation. He co-chaired the AACR Special Conference ¿¿¿Advances in Breast Cancer Research¿¿¿ in 2003, 2005, 2007, 2009 and 2013. He has served as AACR co-chair of the annual San Antonio Breast Cancer Symposium since 2009. He is Deputy Editor of Clinical Cancer Research and member of the Editorial Board of Cancer Cell and six other peer-reviewed journals. He serves on the advisory boards of several NCI Breast Cancer Research Programs and NCI-designated Cancer Centers. In 2013, he was elected as President Elect of the American Association for Cancer Research.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W (2014) Oncologist 19(6): 616-22
    › Primary publication · 24797823 (PubMed) · PMC4041676 (PubMed Central)
  2. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CL (2014) Breast Cancer Res Treat 145(2): 389-99
    › Primary publication · 24722917 (PubMed) · PMC4046906 (PubMed Central)
  3. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL (2014) J Clin Oncol 32(12): 1202-9
    › Primary publication · 24663045 (PubMed) · PMC3986383 (PubMed Central)
  4. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL, Engelman JA (2014) Cancer Cell 25(3): 282-303
    › Primary publication · 24651011 (PubMed) · PMC4018830 (PubMed Central)
  5. Heart failure and breast cancer therapies: moving towards personalized risk assessment. Francis SA, Cheng S, Arteaga CL, Moslehi J (2014) J Am Heart Assoc 3(1): e000780
    › Primary publication · 24584746 (PubMed) · PMC3959702 (PubMed Central)
  6. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL (2014) Breast Cancer Res 16(1): R9
    › Primary publication · 24451154 (PubMed) · PMC3978602 (PubMed Central)